^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + SNK01 (NK cell stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP08.02-128 Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial
Published date:
07/12/2022
Excerpt:
This trial recruited 20 patients with advanced NSCLC with a PD-L1 tumor proportion score of 1% or greater who failed prior frontline platinum-based therapy were randomized to receive pembrolizumab with SNK01 (N=14) or pembrolizumab monotherapy(n=6)….The median PFS was 6.2 vs 1.7 months (Pembrolizumab + NK cells vs Pembrolizumab monotherapy), with significantly higher PFS by log-rank test [HR 0.15 95% CI: 0.05ￚ0.53, p-value: 0.003]....this study shows that NK cells with pembrolizumab could be better than pembrolizumab alone for NSCLC.
